Skip to main content

Market Overview

Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian Cancer


Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (OTCMKTS: OASMY) for Cantrixil under development the treatment of ovarian cancer.

  • The agreement will see Sweden-based Oasmia assume exclusive worldwide rights to develop and commercialize Cantrixil for all indications, with an initial focus on ovarian cancer.
  • Oasmia's lead product, Apealea (paclitaxel micellar), is approved in Europe for adult patients with the first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer, and is in late-stage development in the U.S.
  • Oasmia expects to commence a Phase 2 study of Cantrixil in ovarian cancer in 2022.
  • Under the terms of the agreement, Oasmia will make an upfront payment of $4 million to Kazia, with contingent milestone payments of up to $42 million and double-digit royalties on commercial sales.
  • Cantrixil is a proprietary formulation of the potent and selective third-generation benzopyran, TRX-E-002-1, that targets the entire spectrum of cancer cells, including chemotherapy-resistant tumor-initiating cells (cancer stem cells) thought to be responsible for disease relapse.
  • In December last year, Kazia announced a Phase 1 study's top-line results and determined the maximum tolerated dose of Cantrixil to be 5 mg/kg.
  • Price Action: KZIA closed 3.9% lower at 9.9 on Friday.

Related Articles (KZIA + OASMY)

View Comments and Join the Discussion!

Posted-In: Ovarian CancerBiotech News Health Care Contracts FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at